Need for global cooperation in control of MERS-CoV 2013 marks the tenth anniversary of the severe acute respiratory syndrome (SARS) epidemic that aff ected almost 8000 people and caused 775 deaths.
Just when SARS was about to be forgotten, a new coronavirus associated with severe respiratory disease has entered the scene. The new virus, named Middle East respiratory syndrome coronavirus (MERS-CoV), is in the same family as the SARS coronavirus and has spread to France, Germany, Italy, Tunisia, and the UK. Globally, since September, 2012, WHO has been informed of 81 laboratory-confi rmed cases of infection with MERS-CoV, 45 of which were fatal. The virus emerged fi rst in June, 2012, when it was isolated from the sputum of a patient in Saudi Arabia who died from acute pneumonia and kidney failure after 3 days. MERS-CoV can be transmitted between people, as shown by a report of a hospital outbreak in the eastern province of Al-Hasa, Saudi Arabia, aff ecting 23 people in April and May, 2013. Several other reports have also been published, which concern patients in France, Italy, and the UK who were linked epidemiologically to the Middle East.
The close phylogenetic relationship between the human coronavirus and bat coronavirus might suggest that bats are the ultimate source of MERS-COV. Bats are probably not the immediate contact for human cases because human contact with bats is generally infrequent. However, it is possible that the virus crossed from bats to an agricultural animal, which then spread widely within the Arabian Peninsula. The epidemiology of the virus will become more clear after further surveillance of bats and other reservoirs.
Mild symptoms seem common with MERS-CoV, and they are similar to those of several other illnesses, ranging from infl uenza-like symptoms to pneumonia or severe respiratory illness with cough, shortness of breath, and breathing diffi culties.
Does MERS-CoV have the potential to become pandemic? If so, how will the world prevent such a pandemic? In a recent Lancet study, Romulus Breban and colleagues calculated the ability of the virus to diff use from person to person within a susceptible population. They showed that if the basic reproduction number (R 0 ) is greater than 1, then the number of cases will increase and cause a pandemic eff ect, whereas if it is less than 1, transmission will disappear. They calculated that, in the case of MERS-CoV, R 0 was 0·69 (R 0 of SARS was 0·89). The probability that the R 0 of MERS-CoV would exceed 1 was 5%. According to Breban and colleagues, the virus seems to have diff erent characteristics from SARS including use of diff erent human receptors. DPP4 receptors-peptides that cleave dipeptides from hormones-are implicated in MERS-CoV. SARS adapted to human beings in less than a year. MERS-CoV has been around since 2012 without yet causing a pandemic. Patients infected by MERS-CoV are more likely to be older men and to have comorbid disorders. The proportion of cases that are in health-care workers is lower for MERS-CoV than it was for SARS, whereas the proportion of health-careassociated cases is higher.
The world has learnt from SARS in 2002, H5N1 bird fl u in 2005, and H1N1 swine fl u in 2009, and we know today that better surveillance, new diagnostic techniques, and new infection prevention and control measures are all needed to respond to this new virus.
Worldwide, governments will need to increase levels of awareness of MERS-CoV in all people, but especially in health-care workers. Health-care facilities should be prepared to provide safe care for patients with acute respiratory infections, including MERS-CoV, and prevent amplifi cation of the disease. Better surveillance systems will be of fundamental importance. When new cases are found, countries need to report them to WHO as required by the international health regulations-such reporting is the basis for eff ective international alertness, preparedness, and responses. Countries will be also need to assess and increase their preparedness and readiness should the virus spread.
Investigations and research are urgently needed to better understand the disease source and how MERS-CoV is transmitted, and therapeutic strategies are needed. So far, no data support the use of antiviral drugs, such as ribavirin and interferon, and high-dose steroids should be avoided. Many questions about MERS-CoV, including the source of and main risk factors for infection, remain unanswered. A collaborative and preventive global research eff ort will help close these gaps in knowledge. ■ The Lancet Infectious Diseases 
